What is the address of BIONCISE?

The registered office of BIONCISE is located at Bodemstraat 16 box 3, 3830 Wellen.

Is BIONCISE still active?

Yes. According to the CBE (29 October 2026) BIONCISE is active, legal situation “Normale toestand”, started on 2 March 2017.

Is BIONCISE registered on Peppol?

Yes, BIONCISE is registered on the Peppol network with ID 0208:0671983435.

What is the enterprise number of BIONCISE?

The enterprise number of BIONCISE is BE0671983435.

When was BIONCISE founded?

BIONCISE was founded on 2 March 2017.

Is BIONCISE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 2 March 2017; 5 annual accounts filed, latest fiscal year 2025.

How much profit did BIONCISE make in 2025?

BIONCISE recorded a loss after taxes of € 29,476 in financial year 2025.

What is the revenue of BIONCISE?

As a small company, BIONCISE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 125,449.

Does BIONCISE have a website?

Yes, BIONCISE has a website at bioncise.com.

BIONCISE (Public Limited) - Wellen - BE0671983435

Q: What does BIONCISE do?

BIONCISE is registered with the CBE as active in: Vervaardiging van medische en tandheelkundige instrumenten en benodigdheden. Public Limited, started on 2 March 2017, 1 establishment.

Dossier BIONCISE, printed on 29 October 2026 from databakkes.be/en/0671983435/bioncise. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

BIONCISE from Wellen, company number BE0671983435, closed financial year 2025 with a result of € -29,476 after tax. For that financial year BIONCISE recorded a gross margin of € 125,449 and equity of € 172,478. Compared with financial year 2024, the result moved from € 26,767 to € -29,476. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 13, 2026.

What it is worth Healthy

€ 172,478

▼ 15% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -29,476

▼ still € 26,767 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 68,841

▲ 66% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -147,522.

People and assets in 2025

Wage cost

€ 117,775

▲ 38% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 6,564

▲ 52% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 7,269

▲ 18% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 16,660

▼ 25% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 9,134

▲ 11% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -125,959 Gross margin 2022: € -125,959 First fiscal year in the series	€ 318,935 Gross margin 2023: € 318,935 ▲ € 444,894 vs 2022 (€ -125,959) Favourable step	€ 163,961 Gross margin 2024: € 163,961 ▼ 49% vs 2023 (€ 318,935) Unfavourable step	€ 125,449 Gross margin 2025: € 125,449 ▼ 23% vs 2024 (€ 163,961) Unfavourable step	▼ 23%
Profit after taxes	€ -240,698 Profit after taxes 2022: € -240,698 First fiscal year in the series	€ 119,212 Profit after taxes 2023: € 119,212 ▲ € 359,910 vs 2022 (€ -240,698) Favourable step	€ 26,767 Profit after taxes 2024: € 26,767 ▼ 78% vs 2023 (€ 119,212) Unfavourable step	€ -29,476 Profit after taxes 2025: € -29,476 ▼ € 56,243 vs 2024 (€ 26,767) Unfavourable step	▼ € 56,243
Equity	€ 55,975 Equity 2022: € 55,975 First fiscal year in the series	€ 175,187 Equity 2023: € 175,187 ▲ 213% vs 2022 (€ 55,975) Favourable step	€ 201,954 Equity 2024: € 201,954 ▲ 15% vs 2023 (€ 175,187) Favourable step	€ 172,478 Equity 2025: € 172,478 ▼ 15% vs 2024 (€ 201,954) Unfavourable step	▼ 15%
Total debts	€ 384,807 Total debts 2022: € 384,807 First fiscal year in the series	€ 131,301 Total debts 2023: € 131,301 ▼ 66% vs 2022 (€ 384,807) Favourable step	€ 64,510 Total debts 2024: € 64,510 ▼ 51% vs 2023 (€ 131,301) Favourable step	€ 70,290 Total debts 2025: € 70,290 ▲ 9% vs 2024 (€ 64,510) Unfavourable step	▲ 9%
Cash	-	€ 23,201 Cash 2023: € 23,201 First fiscal year in the series	€ 41,389 Cash 2024: € 41,389 ▲ 78% vs 2023 (€ 23,201) Favourable step	€ 68,841 Cash 2025: € 68,841 ▲ 66% vs 2024 (€ 41,389) Favourable step	▲ 66%
Retained profit	€ -264,025 Retained profit 2022: € -264,025 First fiscal year in the series	€ -144,813 Retained profit 2023: € -144,813 ▲ € 119,212 vs 2022 (€ -264,025) Favourable step	€ -118,046 Retained profit 2024: € -118,046 ▲ € 26,767 vs 2023 (€ -144,813) Favourable step	€ -147,522 Retained profit 2025: € -147,522 ▼ € 29,476 vs 2024 (€ -118,046) Unfavourable step	▼ € 29,476
Bank debt	€ 958 Bank debt 2022: € 958 First fiscal year in the series	€ 60,016 Bank debt 2023: € 60,016 ▲ € 59,058 vs 2022 (€ 958) Unfavourable step	€ 6,173 Bank debt 2024: € 6,173 ▼ 90% vs 2023 (€ 60,016) Favourable step	€ 7,269 Bank debt 2025: € 7,269 ▲ 18% vs 2024 (€ 6,173) Unfavourable step	▲ 18%
Balance sheet total	€ 440,782 Balance sheet total 2022: € 440,782 First fiscal year in the series	€ 306,488 Balance sheet total 2023: € 306,488 ▼ 30% vs 2022 (€ 440,782) Unchanged	€ 266,464 Balance sheet total 2024: € 266,464 ▼ 13% vs 2023 (€ 306,488) Unchanged	€ 242,768 Balance sheet total 2025: € 242,768 ▼ 9% vs 2024 (€ 266,464) Unchanged	▼ 9%

Key figures of BIONCISE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to BIONCISE?

What happened at BIONCISE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 13, 2026 New annual accounts for financial year 2025: loss of € 29,476 (▼ € 56,243 vs 2024). Source: NBB ↗
Mar 2, 2017 New establishment in Wellen. KBO
Mar 2, 2017 Start of the company according to the CBE. KBO

In short

From € 240,698 loss in 2022 to € 29,476 loss in 2025.

Paid € 352 in corporate taxes since 2022.

Best year ever: 2023, with € 119,212 profit.

Original PDFs at the National Bank ↗

Establishments

Establishment units

Physical locations of this company

Registered office

Bodemstraat 16 box 3

3830 Wellen

2.262.452.150

Bodemstraat 16

3830 Wellen

Active since 2 March 2017

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

V&B-DAKWERKEN

€ 1.2 million gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTP bioncise.com

About

Technologies

AngularGoogle FontsPHP

Certifications & Partners

ISO 13485

Hosting & Email

Email provider

Self-hosted

Hosting

NETWORK-SOLUTIONS-HOSTING - Network Solutions, LLC, US

Domain

bioncise.com

Registered

2016-07-27

Registrar

Network Solutions, LLC

Expires

2026-07-27

Website info

HTTPS Nee

Features

Blog Contact page

Security

✗ HTTPS

✓ SPF

✗ DMARC

Details

Company number

0671.983.435

VAT number

BE 0671.983.435

Registered office

Bodemstraat 16 bus 3, 3830 Wellen

Names & denominations

BIONCISE

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

2 March 2017

Peppol

Active · Active since 7 Jan 2026

Contact

bioncise.com

Activities · NACE

Vervaardiging van medische en tandheelkundige instrumenten en benodigdheden

Groothandel in farmaceutische en medische artikelen

Detailhandel in cosmetica en toiletartikelen

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗